Global Oncology Molecular Diagnostics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Product;

Instruments, Reagents, and Others.

By Technology;

Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Isothermic Nucleic Acid Amplification Technology (INNAT), Chips & Microarrays, Sequencing, Mass Spectroscopy, Transcription Mediated Amplification (TMA), and Others.

By Application;

Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Blood Cancer, Liver Cancer, Cervical Cancer, and Other.

By End User;

Hospitals, Diagnostic Centers, Academic & Research Institutes, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn402127091 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Oncology Molecular Diagnostics Market (USD Million), 2021 - 2031

In the year 2024, the Global Oncology Molecular Diagnostics Market was valued at USD 5,114.26 million. The size of this market is expected to increase to USD 11,235.53 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 11.9%.

The global oncology molecular diagnostics market is undergoing a profound transformation, driven by advancements in technology, increasing cancer prevalence, and growing demand for personalized medicine. Molecular diagnostics play a pivotal role in cancer management by enabling early detection, precise diagnosis, and targeted therapy selection based on individual genetic profiles. As a result, there's a burgeoning interest in molecular diagnostic tools among healthcare providers and patients alike.

One of the key drivers propelling the growth of the oncology molecular diagnostics market is the rising incidence of cancer worldwide. With cancer being one of the leading causes of morbidity and mortality globally, there's an urgent need for accurate and timely diagnostic solutions to improve patient outcomes. Molecular diagnostics offer the advantage of detecting cancer at the molecular level, often before symptoms manifest, facilitating early intervention and better treatment outcomes.

The shift towards personalized medicine is significantly influencing the oncology molecular diagnostics landscape. Traditional one-size-fits-all approaches to cancer treatment are being replaced by targeted therapies tailored to the genetic makeup of individual patients. Molecular diagnostic tests, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR), enable healthcare providers to identify specific genetic alterations driving cancer growth and recommend personalized treatment strategies accordingly.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Product
    2. Market Snapshot, By Technology
    3. Market Snapshot, By Application
    4. Market Snapshot, By End User
    5. Market Snapshot, By Region
  4. Global Oncology Molecular Diagnostics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological advancements in molecular diagnostics
        2. Increasing prevalence of cancer worldwide
      2. Restraints
        1. High cost of molecular diagnostic tests
        2. Limited accessibility in developing regions
      3. Opportunities
        1. Growing demand for personalized medicine in oncology
        2. Expanding applications of molecular diagnostics in cancer detection and monitoring
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Oncology Molecular Diagnostics Market, By Product, 2021 - 2031 (USD Million)
      1. Instruments
      2. Reagents
      3. Others
    2. Global Oncology Molecular Diagnostics Market, By Technology, 2021 - 2031 (USD Million)
      1. Polymerase Chain Reaction (PCR)
      2. In-situ Hybridization (ISH)
      3. Isothermic Nucleic Acid Amplification Technology (INNAT)
      4. Chips & Microarrays
      5. Sequencing
      6. Mass Spectroscopy
      7. Transcription Mediated Amplification (TMA)
      8. Others
    3. Global Oncology Molecular Diagnostics Market, By Application, 2021 - 2031 (USD Million)
      1. Breast Cancer
      2. Prostate Cancer
      3. Colorectal Cancer
      4. Lung Cancer
      5. Blood Cancer
      6. Liver Cancer
      7. Cervical Cancer
      8. Other
    4. Global Oncology Molecular Diagnostics Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Diagnostic Centers
      3. Academic & Research Institutes
      4. Others
    5. Global Oncology Molecular Diagnostics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Roche Diagnostics
      2. Abbott Laboratories
      3. Qiagen
      4. Thermo Fisher Scientific
      5. Illumina
      6. Agilent Technologies
      7. Siemens Healthineers
      8. Bio-Rad Laboratories
      9. Sysmex Corporation
      10. Myriad Genetics
  7. Analyst Views
  8. Future Outlook of the Market